Hyundai Bioscience Co Ltd

Hyundai Bioscience has a high price-to-book ratio of 9.12, indicating that the market is valuing the company significantly above its book value. The company's liquidity position is strong, with a current ratio of 2.25, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -17,049,918,860 KRW, and its free cash flow is also negative at -40,997,020,530 KRW, indicating a lack of cash generation from operations. The company's profitability is weak, with a return on equity of -19.98% and a return on assets of -16.93%, both significantly below industry norms. The operating income is negative at -18,675,247,510 KRW, and the net income is also negative at -22,128,347,690 KRW, reflecting poor operational performance. The gross profit margin is low at 6.93%, further highlighting the company's challenges in generating profit from its sales. Geographically and segment-wise, the company's exposure is not disclosed in the available data. However, the revenue concentration data is not available, making it difficult to assess the risk associated with over-reliance on specific markets or product lines. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.16, indicating that it is not heavily leveraged. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The capital expenditure of -20,194,186,400 KRW suggests that the company is investing in its operations, but the negative free cash flow indicates that these investments are not yet generating positive returns. The company's liquidity risk is low, and there are no immediate filing-based liquidity or dilution flags, suggesting that it is not currently facing significant financial distress. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's risk assessment shows that it is not currently facing immediate liquidity or dilution risks, but its poor profitability and negative cash flows suggest that it may need to address these issues in the near future. The company's valuation metrics, such as the enterprise value to revenue ratio of 285.67 and the enterprise value to EBITDA ratio of -53.80, indicate that the company is not currently generating positive earnings and is being valued at a high multiple of its revenue. This suggests that the market may be optimistic about the company's future prospects, despite its current financial performance.